Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dual-LNP
- Development stage
- Preclinical
- Lead developer
- Case Western Reserve University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Inhalation
01
Overview
**dual-LNP** is an experimental, intratumorally administered lipid nanoparticle immunotherapy that co-encapsulates a VISTA-targeting small interfering RNA and the TLR9 agonist CpG oligodeoxynucleotide ODN 1826. It is designed to deliver both cargos to tumor-infiltrating myeloid cells, simultaneously suppressing expression of the immune-checkpoint protein VISTA and activating TLR9-driven innate immune signaling. In murine YUMM1.7 melanoma, B16F10 melanoma, and MC38 colon carcinoma models, the formulation produced potent antitumor immune activation and tumor rejection; it has not been reported as a clinical-stage or marketed product. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11367342/))
- Other names
- dual-action lipid nanoparticledual-LNPVISTA siRNA + CpG LNP
02
Targets
VISTATLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on dual-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dual-LNP.